Ischemia-Modified Albumin Levels in Patients with End-Stage Renal Disease Patients on Hemodialysis: Does Albumin Analysis Method Affect Albumin-Adjusted Ischemia-Modified Albumin Levels?

Basit Öğe Kaydı
dc.contributor.authorKıyıcı, Aysel
dc.contributor.authorMehmetoğlu, İdris
dc.contributor.authorKaraoğlan, Hatice
dc.contributor.authorAtalay, Hüseyin
dc.contributor.authorSolak, Yalçın
dc.contributor.authorTürk, Süleyman
dc.date.accessioned2020-03-26T17:49:21Z
dc.date.available2020-03-26T17:49:21Z
dc.date.issued2010
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractIschemia-Modified albumin (IMA) has been used as an early marker in the evaluation of the patients with acute coronary syndrome. We aimed to evaluate IMA in end-stage renal disease (ESRD) patients on hemodialysis and the effect of albumin methods on albumin-adjusted IMA levels. A total of 30 ESRD patients were included in this study. Serum IMA and albumin levels were measured before and after a hemodialysis session. Albumin concentrations were determined with bromocresol green and bromocresol purple methods. Postdialysis IMA and albumin-adjusted IMA levels with two different albumin methods were significantly increased compared with the predialysis levels (P<0.05). However, we did not find any difference in albumin-adjusted IMA levels in either at the beginning or at the end of the dialysis session. IMA levels increase after hemodialysis, whereas albumin method has no effect on albumin-adjusted IMA levels.en_US
dc.identifier.citationKıyıcı, A., Mehmetoğlu, İ., Karaoğlan, H., Atalay, H., Solak, Y., Türk, S., (2010). Ischemia-Modified Albumin Levels in Patients with End-Stage Renal Disease Patients on Hemodialysis: Does Albumin Analysis Method Affect Albumin-Adjusted Ischemia-Modified Albumin Levels?. Journal of Clinical Laboratory Analysis, 24(4), 273-277. DOI 10.1002/jcla.20399
dc.identifier.doi10.1002/jcla.20399en_US
dc.identifier.endpage277en_US
dc.identifier.issn0887-8013en_US
dc.identifier.issn1098-2825en_US
dc.identifier.issue4en_US
dc.identifier.pmid20626021en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage273en_US
dc.identifier.urihttps://dx.doi.org/10.1002/jcla.20399
dc.identifier.urihttps://hdl.handle.net/20.500.12395/25027
dc.identifier.volume24en_US
dc.identifier.wosWOS:000283412000011en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorKıyıcı, Aysel
dc.institutionauthorMehmetoğlu, İdris
dc.institutionauthorKaraoğlan, Hatice
dc.institutionauthorAtalay, Hüseyin
dc.institutionauthorSolak, Yalçın
dc.institutionauthorTürk, Süleyman
dc.language.isoenen_US
dc.publisherWILEYen_US
dc.relation.ispartofJournal of Clinical Laboratory Analysisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectIschemia-Modified albuminen_US
dc.subjectBromocresol greenen_US
dc.subjectBromocresol purpleen_US
dc.subjectend stage renal diseaseen_US
dc.subjecthemodialysisen_US
dc.titleIschemia-Modified Albumin Levels in Patients with End-Stage Renal Disease Patients on Hemodialysis: Does Albumin Analysis Method Affect Albumin-Adjusted Ischemia-Modified Albumin Levels?en_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
5027.pdf
Boyut:
147.2 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıbbi Biyokimya/Makale Koleksiyonu